BackPenumbra Overview
Penumbra Inc

Penumbra Target Price

See Penumbra's analyst price targets ($320) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$317.6

Average Target Price

$320.000.8% upside

1 analysts in the last 4 months

High: $320 | Low: $320

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-06Evercore ISIVijay Kumar$3200.8% upsideOpen
2026-05-07Evercore ISIVijay Kumar$3355.5% upsideOpen
2026-02-26UBSPriya Sachdeva$37417.8% upsideOpen
2026-02-25Evercore ISI$36013.4% upsideOpen
2026-01-20RBC Capital$37417.8% upsideOpen
2026-01-20Canaccord Genuity$37417.8% upsideOpen
2026-01-16Jefferies$37417.8% upsideOpen
2026-01-16Robert W. BairdDavid Rescott$37417.8% upsideOpen
2026-01-16Leerink PartnersMike Kratky$37417.8% upsideOpen
2026-01-16Truist FinancialRichard Newitter$37417.8% upsideOpen
2026-01-15BTIGRyan Zimmerman$3499.9% upsideOpen
2026-01-15Wells Fargo$37417.8% upsideOpen
2026-01-15Piper SandlerMatt O'Brien$37417.8% upsideOpen
2026-01-05Evercore ISIVijay Kumar$3407.1% upsideOpen
2025-12-18Truist Financial$37016.5% upsideOpen
2025-12-17RBC CapitalShagun Singh$35511.8% upsideOpen
2025-12-17Canaccord Genuity$35913% upsideOpen
2025-12-17NeedhamMike Matson$38822.2% upsideOpen
2025-12-16Robert W. Baird$3458.6% upsideOpen
2025-11-06Evercore ISI$2869.9% downsideOpen
2025-11-06Canaccord GenuityWilliam Plovanic$35511.8% upsideOpen
2025-10-15Truist FinancialRichard Newitter$3005.5% downsideOpen
2025-10-08Needham$3262.6% upsideOpen
2025-10-01Wells Fargo$2908.7% downsideOpen
2025-07-30Truist Financial$3102.4% downsideOpen
2025-07-30Robert W. Baird$28510.3% downsideOpen
2025-07-30UBS$3355.5% upsideOpen
2025-07-30Canaccord Genuity$35010.2% upsideOpen
2025-04-24Robert W. BairdDavid Rescott$3252.3% upsideOpen
2025-04-24Stifel NicolausMathew Blackman$3180.1% upsideOpen
2025-04-15RBC CapitalShagun Singh$3150.8% downsideOpen
2024-12-11Wells FargoLarry Biegelsen$27513.4% downsideOpen
2024-10-31Piper SandlerMatt O'Brien$23526% downsideOpen
2024-10-31Deutsche BankPito Chickering$24124.1% downsideOpen
2024-10-18Piper SandlerMatt O'Brien$22529.2% downsideOpen
2024-10-16Canaccord GenuityJason Mills$23526% downsideOpen
2024-10-15Robert W. BairdDavid Rescott$24423.2% downsideOpen
2024-10-14Truist FinancialRichard Newitter$23526% downsideOpen
2024-10-08RBC CapitalShagun Singh$22230.1% downsideOpen
2024-09-17Stifel NicolausMatthew Blackman$23825.1% downsideOpen
2024-09-03Leerink PartnersMike Kratky$26317.2% downsideOpen
2024-07-31Truist FinancialRichard Newitter$20037% downsideOpen
2024-07-31Wells FargoLarry Biegelsen$15052.8% downsideOpen
2024-07-31Piper SandlerMatt O'Brien$20037% downsideOpen
2024-07-31BTIGRyan Zimmerman$18741.1% downsideOpen
2024-07-31CitigroupJoanna Wuensch$17844% downsideOpen
2024-07-15Morgan StanleyKallum Titchmarsh$21033.9% downsideOpen
2024-07-15BTIGRyan Zimmerman$23227% downsideOpen
2023-08-02Truist FinancialRichard Newitter$3458.6% upsideOpen
2023-02-07Deutsche Bank$2976.5% downsideOpen

Penumbra (PEN) FAQ

The latest target price for PEN is $320. Investors often review this figure alongside Penumbra's historical trend and sector peers before judging valuation or financial health.

Penumbra trades near $317.6 while the consensus target sits at $320 (0.8% upside). Targets are estimates based on earnings forecasts and valuation models; they change when analysts update ratings or revise models. Compare the average with the high and low targets for a fuller picture.

After noting PEN's target price ($320), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Penumbra's target price against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.